Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Has Consensus Price Target of $41.75

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $41.75.

AGIO has been the subject of a number of recent research reports. Citigroup upped their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Bank of America upped their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. raised their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $33.42 on Tuesday. The company has a market capitalization of $2.00 billion, a P/E ratio of -4.77 and a beta of 0.60. The stock’s 50 day moving average price is $33.68 and its 200 day moving average price is $32.39. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -5.82 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Sarah Gheuens sold 30,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AGIO. Sei Investments Co. grew its holdings in Agios Pharmaceuticals by 342.8% in the 1st quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 49,198 shares during the last quarter. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $22,743,000. Seven Fleet Capital Management LP acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $864,000. GW&K Investment Management LLC boosted its position in shares of Agios Pharmaceuticals by 41.5% in the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after acquiring an additional 354,359 shares during the period. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $24,828,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.